Samsung Pharm - Asset Resilience Ratio

Latest as of September 2025: 6.69%

Samsung Pharm (001360) has an Asset Resilience Ratio of 6.69% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Samsung Pharm (001360) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩15.00 Billion

≈ $10.17 Million USD Cash + Short-term Investments

Total Assets

₩224.14 Billion

≈ $151.89 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Samsung Pharm's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 001360 asset base.

Liquid Assets Composition Over Time

This chart breaks down Samsung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Samsung Pharm strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩15.00 Billion	6.69%
Total Liquid Assets	₩15.00 Billion	6.69%

Asset Resilience Insights

Limited Liquidity: Samsung Pharm maintains only 6.69% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Samsung Pharm Industry Peers by Asset Resilience Ratio

Compare Samsung Pharm's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Viatris Inc NASDAQ:VTRS	Drug Manufacturers - Specialty & Generic	1.48%
Dr. Reddy's Laboratories Limited F:RDDA	Drug Manufacturers - Specialty & Generic	11.36%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	Drug Manufacturers - Specialty & Generic	48.48%
Apeloa Pharmaceutical Co Ltd SHE:000739	Drug Manufacturers - Specialty & Generic	0.00%
Zhejiang Huahai Pharmaceutical Co Ltd SHG:600521	Drug Manufacturers - Specialty & Generic	0.35%
Yipinhong Pharmaceutical Co Ltd Class A SHE:300723	Drug Manufacturers - Specialty & Generic	0.66%

Annual Asset Resilience Ratio for Samsung Pharm (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Samsung Pharm.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	2.34%	₩3.00 Billion ≈ $2.03 Million	₩128.45 Billion ≈ $87.05 Million	-14.63pp
2022-12-31	16.96%	₩20.00 Billion ≈ $13.55 Million	₩117.91 Billion ≈ $79.91 Million	-9.37pp
2021-12-31	26.33%	₩38.30 Billion ≈ $25.96 Million	₩145.46 Billion ≈ $98.57 Million	+24.89pp
2020-12-31	1.45%	₩2.59 Billion ≈ $1.75 Million	₩178.73 Billion ≈ $121.12 Million	-14.58pp
2019-12-31	16.03%	₩27.02 Billion ≈ $18.31 Million	₩168.53 Billion ≈ $114.21 Million	-10.47pp
2018-12-31	26.50%	₩42.57 Billion ≈ $28.85 Million	₩160.65 Billion ≈ $108.87 Million	+8.42pp
2017-12-31	18.08%	₩27.88 Billion ≈ $18.89 Million	₩154.19 Billion ≈ $104.50 Million	+13.01pp
2016-12-31	5.08%	₩7.02 Billion ≈ $4.76 Million	₩138.28 Billion ≈ $93.71 Million	-4.91pp
2015-12-31	9.99%	₩13.01 Billion ≈ $8.81 Million	₩130.22 Billion ≈ $88.25 Million	--

pp = percentage points

About Samsung Pharm

KO:001360 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$84.45 Million

₩124.62 Billion KRW

Market Cap Rank

#19950 Global

#1043 in Korea

Share Price

₩1324.00

Change (1 day)

+0.38%

52-Week Range

₩1180.00 - ₩2210.00

All Time High

₩12289.83